Stock comparison
Genmab A/S
McKesson
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
MCK
McKesson
Market cap
$92.09B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | MCK | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 63C | GMAB |
| Benjamin Graham | 64C | 51C | GMAB |
| Philip Fisher | 48D | 47D | GMAB |
| Peter Lynch | 25F | 48D | MCK |
| Joel Greenblatt | 76B | 50C | GMAB |
| Charlie Munger | 68C | 42D | GMAB |
| Terry Smith | 71C | 53C | GMAB |
Side-by-side metrics
| Metric | GMAB | MCK |
|---|---|---|
| Market cap | $16.5B | $92.09B |
| P/E (TTM) | 6.2x | 19.5x |
| EV/EBIT | 12.0x | 14.9x |
| ROIC (TTM) | 43.78% | 31.07% |
| Gross margin | 93.88% | 3.61% |
| Net margin | 18.23% | 1.18% |
| Revenue CAGR 5y | -18.45% | 11.19% |
| EPS CAGR 5y | -23.48% | 51.54% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.42% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Gross margin93.88%vs 3.61%+96%
- Net margin18.23%vs 1.18%+94%
- P/E (TTM)6.2xvs 19.5x+68%
- ROIC (TTM)43.78%vs 31.07%+29%
MCK leads on
- Revenue CAGR 5y11.19%vs -18.45%+161%
- EPS CAGR 5y51.54%vs -23.48%+146%
- Debt / Equity-vs 0.1x+102%
- Dividend yield0.42%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.